LINC00936/microRNA-221-3p Regulates Tumor Progression in Ovarian Cancer by Interacting with LAMA3. 2023

Chenggan Shu, and Weiwei Wang, and Lipei Wu, and Chunrun Qi, and Wenhui Yan, and Wenying Lu, and Jiale Tian, and Anquan Shang
Department of Gynecology, The First People's Hospital of Yancheng, City, Yancheng 224006, P.R. China.

BACKGROUND Ovarian cancer remains a leading cause of mortality in women. It is known that long non-coding RNA (lncRNA) controls various biological processes and pathogenesis of many diseases, including cancers. This study aimed to determine whether LINC00936 and microRNA-221-3p (miR-221-3p) influence the laminin alpha 3 chain gene (LAMA3) in the development of ovarian cancer. METHODS The expressions of LINC00936, miR-221-3p, and LAMA3 in ovarian cancer and adjacent tissues were assessed. Furthermore, ovarian cancer cells were transfected with vectors with overexpressed LINC00936, miR-221-3p mimic, miR-221-3p inhibitor, and si-LAMA3 to elucidate their functions in ovarian cancer cell proliferation, migration, invasion, angiogenesis, and tumorigenesis. The binding relationship between LINC00936 and miR-221-3p and the relationship between miR-221-3p and LAMA3 were verified to explore the mechanism of action of LINC00936 in ovarian cancer. LINC00936 binds to miR-221-3p as a ceRNA and regulates the expression of LAMA3. RESULTS LINC00936 and LAMA3 were poorly expressed, while miR-221-3p was highly expressed in ovarian cancer tissues. Over-expression of LINC00936 contributed to decreasing miR- 221-3p expression and increasing LAMA3 expression. LINC00936 overexpression or miR-221- 3p silencing downregulated the levels of PCNA, MMP-2, MMP-9, and VEGF and decreased cell proliferation, migration, invasion, angiogenesis, and ovarian cancer tumorigenesis. CONCLUSIONS Collectively, overexpression of LINC00936 suppressed the development of ovarian cancer by competitively binding to miR-221-3p and controlling LAMA3 expression. These results could serve as a novel theoretical base for the treatment of ovarian cancer.

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D035683 MicroRNAs Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing. RNA, Small Temporal,Small Temporal RNA,miRNA,stRNA,Micro RNA,MicroRNA,Primary MicroRNA,Primary miRNA,miRNAs,pre-miRNA,pri-miRNA,MicroRNA, Primary,RNA, Micro,Temporal RNA, Small,miRNA, Primary,pre miRNA,pri miRNA

Related Publications

Chenggan Shu, and Weiwei Wang, and Lipei Wu, and Chunrun Qi, and Wenhui Yan, and Wenying Lu, and Jiale Tian, and Anquan Shang
November 2017, The Journal of clinical endocrinology and metabolism,
Chenggan Shu, and Weiwei Wang, and Lipei Wu, and Chunrun Qi, and Wenhui Yan, and Wenying Lu, and Jiale Tian, and Anquan Shang
April 2024, Mutation research,
Chenggan Shu, and Weiwei Wang, and Lipei Wu, and Chunrun Qi, and Wenhui Yan, and Wenying Lu, and Jiale Tian, and Anquan Shang
February 2021, Translational cancer research,
Chenggan Shu, and Weiwei Wang, and Lipei Wu, and Chunrun Qi, and Wenhui Yan, and Wenying Lu, and Jiale Tian, and Anquan Shang
December 2021, Bioengineered,
Chenggan Shu, and Weiwei Wang, and Lipei Wu, and Chunrun Qi, and Wenhui Yan, and Wenying Lu, and Jiale Tian, and Anquan Shang
March 2021, Immunity, inflammation and disease,
Chenggan Shu, and Weiwei Wang, and Lipei Wu, and Chunrun Qi, and Wenhui Yan, and Wenying Lu, and Jiale Tian, and Anquan Shang
January 2013, PloS one,
Chenggan Shu, and Weiwei Wang, and Lipei Wu, and Chunrun Qi, and Wenhui Yan, and Wenying Lu, and Jiale Tian, and Anquan Shang
June 2017, International journal of molecular sciences,
Chenggan Shu, and Weiwei Wang, and Lipei Wu, and Chunrun Qi, and Wenhui Yan, and Wenying Lu, and Jiale Tian, and Anquan Shang
January 2021, Journal of investigative medicine : the official publication of the American Federation for Clinical Research,
Chenggan Shu, and Weiwei Wang, and Lipei Wu, and Chunrun Qi, and Wenhui Yan, and Wenying Lu, and Jiale Tian, and Anquan Shang
April 2023, Cell cycle (Georgetown, Tex.),
Chenggan Shu, and Weiwei Wang, and Lipei Wu, and Chunrun Qi, and Wenhui Yan, and Wenying Lu, and Jiale Tian, and Anquan Shang
August 2015, Journal of hepatology,
Copied contents to your clipboard!